Sugi Predict

Sugi Predict / Targets / TAOK1

TAOK1

Serine/threonine-protein kinase TAO1 · Q7L7X3 · TAOK1 on Sugi Atlas →

58,239 patent compounds predicted against TAOK1, 41,514 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL234334 SCHEMBL234334 1.00 5/20
SCHEMBL232042 SCHEMBL232042 1.00 4/20
SCHEMBL231766 SCHEMBL231766 0.78 4/20
Linifanib Linifanib (SCHEMBL93804) 1.00 3/20
SCHEMBL65790 SCHEMBL65790 0.52 3/20
Hydrochloric Acid Hydrochloric Acid (SCHEMBL58421) 0.52 3/20
SCHEMBL100736 SCHEMBL100736 0.50 3/20
SCHEMBL90887 SCHEMBL90887 0.49 3/20
SCHEMBL90935 SCHEMBL90935 0.49 3/20
Rosoxacin Rosoxacin (SCHEMBL135645) 0.48 3/20
SCHEMBL101240 SCHEMBL101240 0.41 3/20
SCHEMBL201669 SCHEMBL201669 0.41 3/20
Alvocidib Alvocidib (SCHEMBL3651) 1.00 2/20
Alvocidib Alvocidib (SCHEMBL3652) 1.00 2/20
Ruxolitinib Ruxolitinib (SCHEMBL99225) 1.00 2/20
Ruxolitinib Ruxolitinib (SCHEMBL101279) 1.00 2/20
Ruxolitinib Ruxolitinib (SCHEMBL171319) 1.00 2/20
SCHEMBL99245 SCHEMBL99245 0.98 2/20
SCHEMBL99371 SCHEMBL99371 0.98 2/20
SCHEMBL103135 SCHEMBL103135 0.98 2/20

Clinical trials — most relevant to TAOK1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Doxycycline In Lymphangioleiomyomatosis (LAM) PHASE4COMPLETED
Randomized Controlled Study of Postoperative Adjuvant Therapy for Gastric Cancer Using TS-1 or TS-1+PSK PHASE3COMPLETED
A Phase 2 Trial of SCO-101 in Combination With FOLFIRI for Patients With Metastatic Colorectal Cancer (mCRC) With Acquired Resistance to FOLFIRI PHASE1/PHASE2UNKNOWN
Everolimus for Children With Recurrent or Progressive Ependymoma PHASE2COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer PHASE2COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers PHASE1/PHASE2NOT_YET_RECRUITING
Arsenic Trioxide With MAPK Inhibitors and Chemotherapy for Stage 4/M Neuroblastoma PHASE2RECRUITING
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety PHASE2COMPLETED
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid PHASE2COMPLETED
Everolimus (RAD001) Therapy for Epilepsy in Patients With Tuberous Sclerosis Complex (TSC) PHASE1/PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas PHASE2SUSPENDED
Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer PHASE2COMPLETED
Lorlatinib Combinations in Lung Cancer PHASE1/PHASE2UNKNOWN
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer PHASE1/PHASE2COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer PHASE1WITHDRAWN
FAK Inhibitor in Patients With Advanced Solid Tumors PHASE1NOT_YET_RECRUITING
NY-ESO-1 Protein With Montanide and CpG 7909 as Cancer Vaccine in Several Tumors PHASE1COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 EARLY_PHASE1COMPLETED
Treatment of Chronic Lymphocytic Leukemia nanUNKNOWN
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies nanRECRUITING
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children nanCOMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma nanCOMPLETED
A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma（SELINA） nanRECRUITING
Identification of Genes and Pathogenesis Involved in Familial Thoracic Aortic Aneurysm nanCOMPLETED
A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a TAOK1 binder may also engage these)

ProteinNameSimilarity
O88664 — 1.000 O88664 →
Q7ZYJ0 — 1.000 Q7ZYJ0 →
Q5F2E8 — 1.000 Q5F2E8 →
Q6NU21 — 1.000 Q6NU21 →
Q9I9E0 — 1.000 Q9I9E0 →
Q53UA7 — 1.000 Q53UA7 →
Q6GPK9 — 1.000 Q6GPK9 →
Q8BYC6 — 1.000 Q8BYC6 →
Q6DD27 — 1.000 Q6DD27 →
TAOK3 Serine/threonine-protein kinase TAO3 1.000 landscape →
P46549 — 0.999 P46549 →
Q5R4F3 — 0.997 Q5R4F3 →
F1NBT0 — 0.994 F1NBT0 →
Q0KHQ5 — 0.994 Q0KHQ5 →
O55098 — 0.991 O55098 →
Q7SY52 — 0.991 Q7SY52 →
Q0IHQ8 — 0.991 Q0IHQ8 →
B7ZR30 — 0.991 B7ZR30 →
STK10 Serine/threonine-protein kinase 10 0.988 landscape →
E1BK52 — 0.988 E1BK52 →
E9PTG8 — 0.987 E9PTG8 →
O43295 — 0.987 O43295 →
PTK2 Focal adhesion kinase 1 0.985 landscape →
Q7SYB5 — 0.985 Q7SYB5 →
CDC42BPB Serine/threonine-protein kinase MRCK beta 0.984 landscape →
O35346 — 0.984 O35346 →
CDC42BPA Serine/threonine-protein kinase MRCK alpha 0.984 landscape →
Q13136 — 0.983 Q13136 →
Q812A2 — 0.983 Q812A2 →
P34152 — 0.982 P34152 →